Buy Antabuse Online – disulfiram



Adjuvant in the prevention of relapses during alcohol dependence.

How to take Antabuse


Oral route.

1 tablet per day.

Administration mode

Swallow the tablet with half a glass of water, in the morning at breakfast after abstinence from alcohol for at least 24 hours.

Possible side effects of Antabuse

  • Confusion
  • Neuropsychic impairment
  • Headache
  • Drowsiness
  • Polyneuropathy
  • Optic neuritis
  • Amnesia
  • Convulsions
  • Encephalopathy
  • Hypertension
  • Dysgeusia
  • Nausea
  • Vomiting
  • Gastralgia
  • Diarrhea
  • Bad breath
  • Abnormal smell of faeces
  • Elevation of transaminases
  • Hepatitis
  • Cytolytic hepatitis
  • Hepatic insufficiency
  • Fulminant hepatitis
  • Allergic dermatitis
  • Tired
  • Tachycardia
  • Rhythm disturbances
  • Angina attack
  • Myocardial infarction
  • Sudden death
  • Flushing of the face
  • Hypotension
  • Cardiovascular collapse
  • Respiratory depression
  • Feeling unwell
  • Skin erythema
  • Liver toxicity
  • Asthenia
  • Anorexia
  • Abdominal pain
  • Jaundice

Adverse reactions were ranked in order of frequency using the following convention:

very common ≥ 1/10; common ≥ 1/100, <1/10; uncommon ≥1 / 1000, <1/100; rare ≥ 1/10000, <1/1000; very rare <1 / 10,000, frequency not known (cannot be estimated from the available data).

Adverse reactions related to disulfiram

Psychiatric disorders

Frequency not known:

Confusional state, neuropsychic disorders.

Nervous system disorders

Very common :





Polyneuropathy (s).

Frequency not known:

Optic neuritis, amnesia, convulsions, encephalopathy usually reversible after stopping disulfiram.

Vascular disorders

Frequency not known:


Gastrointestinal disorders



Frequency not known:

Nausea, vomiting, gastralgia, diarrhea

Bad breath

Abnormal stool odor.

Hepatobiliary disorders

Frequency not known:

· Elevations of transaminases are common. Cases of hepatitis (mainly cytolytic) have been reported; some severe cases are accompanied by liver failure or fulminant hepatitis which may justify a liver transplant or lead to death. (see section Warnings and precautions for use).

Skin and subcutaneous tissue disorders 

Frequency not known:

Allergic dermatitis.

General disorders and administration site conditions

Very common :


Adverse reactions related to the disulfiram-alcohol combination

Nervous system disorders

Frequency not known:

Neurological accidents (mental confusion, encephalopathy and convulsions)

Cardiac disorders

Frequency not known:

Tachycardia, cardiac arrhythmias, angina attack, myocardial infarction, sudden death

Vascular disorders

Frequency not known:

Flushing of the face, hypotension, cardiovascular collapse.

Respiratory, thoracic and mediastinal disorders

Frequency not known:

Respiratory depression.

Gastrointestinal disorders

Frequency not known:

Vomiting, nausea.

Skin and subcutaneous tissue disorders

Frequency not known:


General disorders and administration site conditions 

Frequency not known:

Feeling unwell.

Reporting of suspected adverse reactions

The reporting of suspected adverse reactions after authorization of the drug is important. It allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals report any suspected adverse reactions via the national reporting system: National Agency for Medicines and Health Products Safety (ANSM) and network of Regional Pharmacovigilance Centers

Antabuse Contraindications

  • Severe hepatic impairment
  • Renal failure
  • Severe respiratory failure
  • Diabetes
  • Neuropsychic impairment
  • Epilepsy
  • Cardiovascular involvement
  • Alcohol intake for less than 24 hours
  • Pregnancy
  • Lack of effective female contraception
  • Feeding with milk

This medication is contraindicated in the following cases:

Hypersensitivity to disulfiram or to any of the other constituents of the tablet,

Severe hepatic impairment

·Renal failure,

Severe respiratory failure


– Neuropsychic attacks,


Cardiovascular impairment

Taking alcoholic drinks or medicines containing alcohol for less than 24 hours.

Precautions for use Antabuse

  • Asthenia
  • Anorexia
  • Nausea
  • Vomiting
  • Abdominal pain
  • Jaundice
  • Transaminase monitoring
  • Transaminases> 3 ULN
  • Nickel eczema
  • Woman of childbearing age

Special warnings

Related to disulfiram alone

Cases of severe liver toxicity which may require liver transplantation or result in death have been reported:

In the event of suggestive signs (asthenia, anorexia, nausea, vomiting, abdominal pain or jaundice), a clinical examination and biological control of the hepatic functions should be undertaken immediately (see section Undesirable effects).

Linked to the disulfiram alcohol combination

Patients should be informed of the risk of an anti-abuse effect (see section Interactions with other medicinal products and other forms of interactions).

The disulfiram-alcohol reaction: this reaction (antabuse effect) occurs in patients treated with disulfiram when absorbing alcohol, even in small quantities: beware of the presence of alcohol in the composition of other drugs ( especially in drinkable solutions), in food, but also when using toiletries such as aftershaves and perfumes.

The unpleasant symptoms (flushing of the face, erythema, nausea and vomiting, feeling sick, tachycardia, hypotension) occur 10 minutes after ingestion of alcohol and last from ½ hour to several hours.

Reactions with alcohol may occur for up to 2 weeks after stopping disulfiram. More severe reactions have been reported: cardiac arrhythmias, angina attack, cardiovascular collapse, myocardial infarction, sudden death, respiratory depression, neurological accidents (mental confusion, encephalopathy and convulsions).

Concomitant intake of disulfiram is not recommended with:

Alcohol and medicines containing alcohol


– metronidazole,

– phenytoin, fosphenytoin (see section Interactions with other medicinal products and other forms of interactions).

Precautions for use

This medication should only be administered after a thorough medical examination (clinical and biological).

Perform a biological control of hepatic functions, including a dosage of transaminases, before the start of treatment with disulfiram (see section Contraindications) then regularly, at least once a month, in particular during the first 3 months of treatment. Raising transaminases to three times the upper normal limit requires immediate and definitive discontinuation of treatment. Patients should then be followed closely until the liver function tests are normal.

Disulfiram should be used with caution in patients with nickel eczema, due to an increased risk of developing hepatitis (see section 4.8).

Disulfiram should never be administered to the patient without their knowledge.

The use of disulfiram is not recommended during pregnancy, whatever the term, and in women of childbearing potential not using contraception (see section Fertility, pregnancy and lactation).

Antabuse Drugs interactions

Not recommended associations

+ Alcohol (drink or excipient)

Antabuse effect (heat, redness, vomiting, tachycardia).

Avoid taking alcoholic beverages and drugs containing alcohol. Take into account the complete elimination of drugs by referring to their half-life before resuming alcoholic beverages or drugs containing alcohol.

+ Isoniazid

Behavior and coordination disorders.

+ Metronidazole

Risk of episodes of acute psychosis or confusional state, reversible upon discontinuation of the association.

+ Phenytoin (and, by extrapolation fosphenytoin)

Significant and rapid increase in plasma concentrations of phenytoin with toxic signs (inhibition of its metabolism).

If it cannot be avoided, monitor clinical and plasma phenytoin concentrations during treatment with disulfiram and after its discontinuation.

Combinations subject to precautions for use

+ Antivitamin K

Increased effect of antivitamin K and risk of bleeding.

More frequent control of the INR. Adjustment of the dose of the antivitamin K during treatment with disulfiram and 8 days after its discontinuation.

Associations to take into account

+ Cocaine 

Disulfiram may cause inhibition of cocaine metabolism resulting in a marked increase in plasma cocaine concentration and an increased risk of QT interval prolongation.

Use disulfiram with caution in patients taking cocaine.

Not applicable.

Overdose of Antabuse


An overdose with disulfiram alone can lead to severe neurological damage such as encephalopathy and may be responsible for disturbances of consciousness such as confusion and coma, convulsions and extrapyramidal syndromes. The combination of a disulfiram-ethanol overdose can lead to coma or delirium, cardiovascular collapse with sometimes neurological complications.

To behave

Treatment is symptomatic.

Pregnancy and breast feeding


Animal data do not allow a conclusion and clinical data are insufficient.

The use of disulfiram is therefore not recommended during pregnancy, whatever the term, and in women of childbearing potential not using contraceptive measures.

The appearance of a significant anti-abuse effect when taking alcohol can have serious consequences for the fetus.

Feeding with milk

In the event of treatment with disulfiram, breast-feeding is not recommended.

Appearance and shape


20 tablets in tube (Polypropylene) closed with a stopper (Polyethylene) with desiccant.

Antabuse Composition

Active ingredientCompressed
Disulfiram500 mg *

* per unit doseActive ingredients: Disulfiram Excipients: Povidone , Carmellose sodium , Magnesium stearate , Microcrystalline cellulose

No excipient with known effect is not present in the composition of this drug

Action mechanism of Antabuse

Pharmacotherapeutic group: N: Central nervous system, ATC code: N07BB01.

Disulfiram is an inhibitor of many enzymes.

Inhibition of acetaldehyde dehydrogenase leads to an increase in the concentration of acetaldehyde, a metabolite of ethyl alcohol responsible for unpleasant manifestations: flushing of the face, nausea and vomiting, feeling of malaise, tachycardia, hypotension.

Other information

  • Pharmaceutical form: Tablet
  • Route of administration: Oral
  • ATC code: N07BB01
  • Pharmacotherapeutic group: Disulfiram
  • Prescription and dispensing conditions: List I
  • Specialty Identifier Code (CIS): 61500746
  • Actual benefit (SMR): Important, Important
  • Laboratory holder AMM: Sanofi aventis France (11/18/1997)
  • Operating laboratory: Sanofi aventis france

This drug does not belong to any generic group.


  • Summary of Product Characteristics (SPC) of French and European marketing authorizations (AMM)
  • Drug interactions booklet from the National Agency for the Safety of Medicines and Health Products (ANSM)
  • ANSM generic directory
  • Reference documents from the Haute Autorité de Santé (HAS): transparency sheets, good use sheets, SAM documents (Decision Support System for Medicines)
  • Prices and reimbursements from the Economic Committee for Health Products (CEPS)
  • Information from laboratories holding Marketing Authorization (see above in the “Other information” tab of this page)
  • Information wholesalers distributors
  • Health insurance (CNAMTS): guide to long-term assignments (ALD)
  • Technical Agency for Information on Hospitalization (ATIH): CIM10 classification
  • World Health Organization (WHO): ATC classification
  • European Pharmacopoeia: Standard Terms and EPhMRA Classification
  • Ministry of Health: doping substances
Scroll to Top